Alumis Shares Rise on Plans to Share Trial Data for Plaque Psoriasis Treatment

Dow Jones

01/06

By Kelly Cloonan

Shares of Alumis gained on plans to share topline data from a Phase 3 trial evaluating envudeucitinib to treat moderate-to-severe plaque psoriasis.

The stock rose 8.9% to $9.05 in after-hours trading on Monday. Through market close, shares have more than doubled in the past three months.

The biopharmaceutical company said it will report the data on Tuesday and host a conference call to discuss the results the same day.

The company had said in November it expected to share the topline results early in the first quarter. The data, as well as expected results from a trial evaluating the therapy in systemic lupus erythematosus, could validate envu's differentiated profile and unlock further opportunities across immune-mediated diseases, Alumis said at the time.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

January 05, 2026 18:12 ET (23:12 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2601853109"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601853109\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601853109?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 07:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601853109","market":"hk","top_or_hot":-1,"title":"Alumis Shares Rise on Plans to Share Trial Data for Plaque Psoriasis Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Alumis gained on plans to share topline data from a Phase 3 trial evaluating envudeucitinib to treat moderate-to-severe plaque psoriasis. \n</p>\n<p>\n  The stock rose 8.9% to $9.05 in after-hours trading on Monday. Through market close, shares have more than doubled in the past three months. \n</p>\n<p>\n  The biopharmaceutical company said it will report the data on Tuesday and host a conference call to discuss the results the same day. \n</p>\n<p>\n  The company had said in November it expected to share the topline results early in the first quarter. The data, as well as expected results from a trial evaluating the therapy in systemic lupus erythematosus, could validate envu's differentiated profile and unlock further opportunities across immune-mediated diseases, Alumis said at the time. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 05, 2026 18:12 ET (23:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alumis Shares Rise on Plans to Share Trial Data for Plaque Psoriasis Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlumis Shares Rise on Plans to Share Trial Data for Plaque Psoriasis Treatment\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-01-06 07:12</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Alumis gained on plans to share topline data from a Phase 3 trial evaluating envudeucitinib to treat moderate-to-severe plaque psoriasis. \n</p>\n<p>\n  The stock rose 8.9% to $9.05 in after-hours trading on Monday. Through market close, shares have more than doubled in the past three months. \n</p>\n<p>\n  The biopharmaceutical company said it will report the data on Tuesday and host a conference call to discuss the results the same day. \n</p>\n<p>\n  The company had said in November it expected to share the topline results early in the first quarter. The data, as well as expected results from a trial evaluating the therapy in systemic lupus erythematosus, could validate envu's differentiated profile and unlock further opportunities across immune-mediated diseases, Alumis said at the time. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 05, 2026 18:12 ET (23:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALMS","symbol_name":"Alumis Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2601853109","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601853109","pubTimestamp":1767654720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Alumis gained on plans to share topline data from a Phase 3 trial evaluating envudeucitinib to treat moderate-to-severe plaque psoriasis.The stock rose 8.9% to $9.05 in after-hours trading on Monday. Through market close, shares have more than doubled in the past three months.The biopharmaceutical company said it will report the data on Tuesday and host a conference call to discuss the results the same day.The company had said in November it expected to share the topline results early in the first quarter. The data, as well as expected results from a trial evaluating the therapy in systemic lupus erythematosus, could validate envu's differentiated profile and unlock further opportunities across immune-mediated diseases, Alumis said at the time.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALMS":"Alumis Inc.","BK4007":"制药"},"translate_title":"Alumis计划分享斑块型银屑病治疗试验数据，股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALMS":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of Alumis gained on plans to share topline data from a Phase 3 trial evaluating envudeucitinib to treat moderate-to-severe plaque psoriasis. \n\n\n  The stock rose 8.9% to $9.05 in after-hours trading on Monday. Through market close, shares have more than doubled in the past three months. \n\n\n  The biopharmaceutical company said it will report the data on Tuesday and host a conference call to discuss the results the same day. \n\n\n  The company had said in November it expected to share the topline results early in the first quarter. The data, as well as expected results from a trial evaluating the therapy in systemic lupus erythematosus, could validate envu's differentiated profile and unlock further opportunities across immune-mediated diseases, Alumis said at the time. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 05, 2026 18:12 ET (23:12 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}